Atopic Dermatitis

Researchers have found a way to evaluate the cutaneous biomarkers of atopic dermatitis via a minimally invasive method using tape strips, which may offer insight into tracking pediatric treatment responses in the future, according to recent findings published in JAMA Dermatology.

An estimated 16.5 million adults in the U.S. have atopic dermatitis, according to the Asthma and Allergy Foundation of America.

The department of dermatology at the University of Michigan Medical School has been awarded $3.9 million from the NIH to establish the University of Michigan Skin Biology and Diseases Resource-based Center to foster interdisciplinary collaboration, according to a university press release.

Findings from a 12-week phase 2b study show significant improvement in the signs and symptoms of atopic dermatitis with once-daily treatment of an oral Janus kinase 1 selective inhibitor, abrocitinib 100 mg or 200 mg.

Relying primarily on patient global assessments falls short in determining comprehensive disease severity, but by adding the Skindex instrument or other measures, clinicians may obtain a better evaluation of patient quality of life, according to a panel of stakeholders on behalf of the International Dermatology Outcome Measures and the American Academy of Dermatology.

Treated atopic eczema was associated with a 14% increase in the risk for newly diagnosed depression and a 17% increase in a subsequent anxiety diagnosis, regardless of eczema severity, according to a study.

In the most popular article last week on Healio Dermatology, researchers tallied the cost of all dermatology-related hospital admissions at $27.8 billion from 2010 to 2014, while the cost of all calendar year same-cause readmissions was $2.54 billion.

A nonmelanoma skin cancer risk prediction model using readily available information in the electronic medical records system and a deep learning approach appeared to demonstrate robust discrimination, according to findings published in JAMA Dermatology.

The exacerbation or development of head and neck dermatitis in patients treated for atopic dermatitis with dupilumab may be caused by a dysregulation in the balance of the T helper cell signaling pathway, according to a research letter in JAMA Dermatology.

Dupilumab significantly improved atopic dermatitis signs, symptoms and quality of life in Asian, black and white patients, according to a pooled analysis of three phase 3 trials.